Janumet XR CP CO Pack Tablet

Janumet XR CP CO Pack Tablet is an anti-diabetic medicine. It is a combination of Sitagliptin (100mg) and Metformin (1000mg). It is prescribed to treat type 2 diabetes mellitus in adults. It works by controlling high blood sugar levels in people with diabetes and also prevents from serious complications related with diabetes such as kidney damage, blindness and may also reduce chances of having a heart attack or stroke. It should be taken with food at the same time each day to get effective results. Don't take more than the recommended dose

• Type 2 diabetes mellitus

Janumet XR CP CO Pack Tablet may cause some side effects that vary from one patient to another. Most side effects do not require any medical attention and disappear as your body adjusts to the medicine.
Common side effects include:

• Headache
• Diarrhea
• Upper respiratory tract infection

Seek medical attention in case of any unusual or severe side effects immediately.

• Take Janumet XR CP CO Pack Tablet in dosage as prescribed by the doctor. Dosage and the duration determined as per the patients health condition.
• This tablet should be swallowed as a whole with water. Don't crush, chew, or break the tablet. It should be taken with food. Never skip a dose or double dose.
  

• Janumet XR CP CO Pack Tablet is an anti-diabetic medicine. It is a combination of Sitagliptin (100mg) and Metformin (1000mg). As a sulfonylurea, sitagliptin minimizes blood sugar by stimulating the pancreas to secrete more insulin.
• Metformin is a biguanide that increases the body's tolerance to insulin, reduces the liver's synthesis of glucose, and slows down the intestines' absorption of glucose.
  

• Goldstein, B. J., Feinglos, M. N., Lunceford, J. K., Johnson, J., Williams-Herman, D. E., & Sitagliptin 036 Study Group. (2007). Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes care, 30(8), 1979-1987. https://pubmed.ncbi.nlm.nih.gov/17485570/
• Hayes, J., Anderson, R., & Stephens, J. W. (2016). Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy. Drug Design, Development and Therapy, 2263-2270. https://pubmed.ncbi.nlm.nih.gov/27486305/
• Williams-Herman, D., Johnson, J., Teng, R., Luo, E., Davies, M. J., Kaufman, K. D., ... & Amatruda, J. M. (2009). Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current Medical Research and Opinion, 25(3), 569-583. https://pubmed.ncbi.nlm.nih.gov/19232032/
• Chwieduk, C. M. (2011). Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus. Drugs, 71(3), 349-361. https://pubmed.ncbi.nlm.nih.gov/21319871/
• Williams‐Herman, D., Johnson, J., Teng, R., Golm, G., Kaufman, K. D., Goldstein, B. J., & Amatruda, J. M. (2010). Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 12(5), 442-451. https://pubmed.ncbi.nlm.nih.gov/20415693/